Skip to main content
. 2016 Sep 1;11(9):e0161753. doi: 10.1371/journal.pone.0161753

Fig 3. Peak neutralizing antibody titers.

Fig 3

TZM-bl neutralizing antibody titers by treatment group at peak immunogenicity (2 weeks post last vaccination) over the panel of 5 virus isolates (Tier 1: Clade B [MN.3, SF162], Clade C [MW925]; Tier 2: Clade C [Du151.2, TV1.21]). Each dot represents an individual, with data from responders in red and non-responders in blue. Box plots based on data from responders only are shown. The mid-line of the box denotes the median and the ends of the box denote the 25th and 75th percentiles. Whiskers extend to the extreme data points that are no more than 1.5 times the interquartile range or if no value meets this criterion, to the data extremes. The number and percent positive responders in each group are shown above the graphs. T1: MVA prime, sequential gp140 boost (M/M/P/P); T2: (MP/MP): concurrent MVA/gp140; T3 (D/D/M/M): DNA prime, sequential MVA boost; T4 (D/D/MP/MP): DNA prime, concurrent MVA/gp140 boost) or placebo.